The Companies and Markets Show: Elixirr, Vodafone and Judges Scientific

episode

Investors' Chronicle not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-29-2026 7AM EDT 4 min · 29 Sep 2026 · NPR News Now

7AM ET 09/29/2026 Newscast 3 min · 29 Sep 2026 · Fox News Hourly Update

Most replayed moment: The hidden dangers of hearing loss | Prof. Marcelo Rivolta 8 min · 29 Sep 2026 · ZOE Science & Nutrition

Overmedicated To Death: Former FDA Officer on Presley Gerber & The Psychiatric Crisis in America w/ Dr. Mary Talley Bowden, Dr. Josef Witt-Doerring & Ronald Owens Jr. – Ask Dr. Drew – Ep 670 1h 19m · 29 Sep 2026 · Ask Dr. Drew

Federal boost for Navitas 6 min · 29 Sep 2026 · Wall Street Breakfast

SpaceX Starship Finally Reached Orbit & Why Dudes Are Becoming Cat Dads 29 min · 29 Sep 2026 · Morning Brew Daily

Report any issue

Source

Recorded22 Sep 2023

Publisherfeeds.acast.com ↗

Handlerec:10067522

Show notes

The episode begins with Jemma Slingo, who runs through the recent results from listed management consultant Elixirr. What can the interim figures tell us about future growth?It’s then on to Arthur Sants, who discusses Vodafone, a company that features in our most recent cover story on Income Majors. What could the merger with Three bring to the company? And what can we expect the new chief executive to do?Last up, Mark Robinson shares his thoughts on ‘buy and build’ specialist Judges Scientific. Can its bread-and-butter strategy still thrive in tough economic conditions? Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in